The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Pancreatic Cancer Detection Consortium (PCDC) Prospective Cohorts
Official Title: Pancreatic Cancer Detection Consortium (PCDC) Prospective Cohorts
Study ID: NCT06271291
Brief Summary: This study evaluates individuals without pancreatic cancer, but who have been determined to be at higher-than-average lifetime risk of developing pancreatic cancer to help detect pancreatic cancer or other cancers at an earlier time when they might be more easily treated and cured.
Detailed Description: PRIMARY OBJECTIVES: I. To develop a cohort (biobank of biospecimens and data) of subjects without pancreatic cancer who are at highrisk for pancreatic cancer due to: a strong family history, a mutation in a known pancreatic cancer predisposition gene, or fukuoka worrisome or high-risk pancreatic cysts. II. To follow the cohort subjects longitudinally and collect biospecimens and follow-up data and record medical outcomes. III. To make biospecimen available to PCDC-approved projects to validate potential biomarkers for performance using nested case-control prospective designs. OUTLINE: This is an observational study. Participants undergo blood sample collection, complete questionnaires, have their medical records reviewed and undergo pancreatic cyst fluid collection during standard of care endoscopic ultrasounds fine needle aspiration.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
City of Hope, Duarte, California, United States
Mayo Clinic in Rochester, Rochester, Minnesota, United States
University of Pittsburgh, Pittsburgh, Pennsylvania, United States
Name: Ann L. Oberg, Ph.D.
Affiliation: Mayo Clinic in Rochester
Role: PRINCIPAL_INVESTIGATOR